Sunesis Pharmaceuticals Inc (SNSS):企業の財務・戦略的SWOT分析

◆英語タイトル:Sunesis Pharmaceuticals Inc (SNSS) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15774
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,375見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,125見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Sunesis Pharmaceuticals Inc (SNSS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company’s Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.

Sunesis Pharmaceuticals Inc Key Recent Developments

Mar 07,2019 Sunesis Pharmaceuticals reports fourth quarter and full-year 2018 financial results and recent highlights
Jan 02,2019 Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
Nov 05,2018 Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights
Aug 07,2018 Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Sunesis Pharmaceuticals Inc – Key Facts
Sunesis Pharmaceuticals Inc – Key Employees
Sunesis Pharmaceuticals Inc – Key Employee Biographies
Sunesis Pharmaceuticals Inc – Major Products and Services
Sunesis Pharmaceuticals Inc – History
Sunesis Pharmaceuticals Inc – Company Statement
Sunesis Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Sunesis Pharmaceuticals Inc – Business Description
Sunesis Pharmaceuticals Inc – Corporate Strategy
Sunesis Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Sunesis Pharmaceuticals Inc – Strengths
Sunesis Pharmaceuticals Inc – Weaknesses
Sunesis Pharmaceuticals Inc – Opportunities
Sunesis Pharmaceuticals Inc – Threats
Sunesis Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 07, 2019: Sunesis Pharmaceuticals reports fourth quarter and full-year 2018 financial results and recent highlights
Jan 02, 2019: Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
Nov 05, 2018: Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights
Aug 07, 2018: Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights
Jul 09, 2018: Sunesis Pharmaceuticals Announces Senior Management Changes
May 08, 2018: Sunesis Pharmaceuticals Announces First Quarter 2018 Financial Results
Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights
Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Sunesis Pharmaceuticals Inc, Key Facts
Sunesis Pharmaceuticals Inc, Key Employees
Sunesis Pharmaceuticals Inc, Key Employee Biographies
Sunesis Pharmaceuticals Inc, Major Products and Services
Sunesis Pharmaceuticals Inc, History
Sunesis Pharmaceuticals Inc, Subsidiaries
Sunesis Pharmaceuticals Inc, Key Competitors
Sunesis Pharmaceuticals Inc, Ratios based on current share price
Sunesis Pharmaceuticals Inc, Annual Ratios
Sunesis Pharmaceuticals Inc, Annual Ratios (Cont...1)
Sunesis Pharmaceuticals Inc, Interim Ratios
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Sunesis Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Sunesis Pharmaceuticals Inc, Ratio Charts
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Sunesis Pharmaceuticals Inc (SNSS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • General Communication, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' General Communication, Inc. Mer …
  • JPMorgan Chase and Co.:企業の戦略・SWOT・財務分析
    SummaryJPMorgan Chase and Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key …
  • Sonangol E.P.:企業のM&A・提携・投資分析
    Sonangol E.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sonangol E.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Jutal Offshore Oil Services Limited (3303):企業のM&A・提携動向(石油・ガス分野)
    Summary Jutal Offshore Oil Services Limited (Jutal), a subsidiary of Cheung Hing Investments Limited is an energy service provider that offers offshore engineering, technical support, and oil and gas equipments. The company offers oil and gas installation services such as oil and gas processing syst …
  • Maple Energy plc:企業のM&A・提携動向(石油・ガス分野)
    Summary Maple Energy plc (Maple) is an energy service provider that explores and develops various aspects of energy industry. The company offers operations like crude oil exploration and production; refining, marketing and distribution of hydrocarbon products; ethanol production based on sugar cane; …
  • Monarch Energy Limited (CHX):企業概要、財務及び戦略的SWOT分析
    Summary Monarch Energy Limited (Monarch Energy) is an independent upstream energy company. The company carries out the exploration and development of petroleum and natural gas reserves, and mineral properties. It also holds interests in producing wells in the province of Alberta. Monarch Energy owns …
  • Profectus BioSciences, Inc.(製薬・医療分野):企業M&A動向
    Summary Profectus BioSciences, Inc. (Profectus) is a biotechnology company. The company develops vaccines to prevent and treat viral diseases and malaria through the application of pDNA and rVSV platform. Its products include boost system of vaccine, therapeutic vaccines, cancer vaccines, and other …
  • Sealed Air Corporation:企業のM&A・事業提携・投資動向
    Sealed Air Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sealed Air Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Jaiprakash Power Ventures Limited (JPPOWER):企業のM&A・提携動向(エネルギー分野)
    Summary Jaiprakash Power Ventures Limited (Jaiprakash Power), a wholly owned subsidiary of Jaiprakash Associates Limited, is a generation and transmission utility. The company owns and operates hydro and thermal power plants, which include Baspa-II hydroelectric project; Jaypee Vishnuprayag Hydro Po …
  • ERG Renew S.p.A.:企業のM&A・提携動向(発電分野)
    Summary ERG Renew S.p.A. (ERG Renew), formerly Entad S.p.A., a subsidiary of ERG S.p.A, is a power company that generates electricity from renewable sources. The company generates electricity mainly through wind. ERG Renew and its subsidiaries operate in Italy, France, Bulgaria/Romania, Germany, and …
  • Vinci Construction UK Ltd:企業の戦略・SWOT・財務情報
    Vinci Construction UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Vinci Construction UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Bioplus Life Sciences Private Limited:企業の戦略・SWOT・財務分析
    SummaryBioplus Life Sciences Private Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of th …
  • Tizona Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tizona Therapeutics Inc (Tizona Therapeutics) is an immunology company which develops treatments for cancer and autoimmune disorders. Its lead product candidate anti-CD39 antibody inhibits the breakdown of excessive ATP released from dying tumor cells to immune suppressive adenosine leading …
  • Australian Broadcasting Corporation:企業の戦略的SWOT分析
    Australian Broadcasting Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Pathfinder Energy Pty Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Pathfinder Energy Pty Ltd (Pathfinder) is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas resources. The company acquires exploration permits and matures prospects using geophysics and geology. It maintains exploration licenses in …
  • Siemens Medical Solutions USA Inc:医療機器:M&Aディール及び事業提携情報
    Summary Siemens Medical Solutions USA Inc (Siemens Medical USA), a subsidiary of Siemens Healthcare GmbH is a medical device company that designs, develops, manufactures and distributes medical devices and technologies for diagnostic markets. The company offers products in the areas of medical imagi …
  • Sunningdale Tech Ltd (T35):企業概要、財務及び戦略的SWOT分析
    Summary Sunningdale Tech Ltd (Sunningdale) is a chemical company. The company manufactures precision plastic components. It turnkey plastic solutions include product and mould designs, mould fabrication, injection moulding, complementary finishings, and precision assembly of complete products. Sunni …
  • Nuance Communications, Inc.:企業の戦略・SWOT・財務情報
    Nuance Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nuance Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Kuros Biosciences AG (KURN):製薬・医療:M&Aディール及び事業提携情報
    Summary Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as we …
  • Acerinox, S.A. (ACX):企業概要・SWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Acerinox, S.A." The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric strictly follows a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆